Phenotypic characterization of patient dengue virus isolates in BALB/c mice differentiates dengue fever and dengue hemorrhagic fever from dengue shock syndrome

Virology Journal

Volumn 8, Issue , 2011, Pages

  Tuiskunen, Anne ^a,b,c   Wahlström, Maria ^b   Bergström, Jakob ^b   Buchy, Philippe ^d   Leparc Goffart, Isabelle ^c   Lundkvist, Åke ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c French Army Institute of Biomedical Research (IRBA)   (France)

^d INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

Author keywords

clinical isolate; cytokines; dengue hemorrhagic fever; dengue virus; flavivirus; mouse model; tropism

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DENGUE; DENGUE SHOCK SYNDROME; DENGUE VIRUS; FEMALE; HUMAN; MOUSE; NONHUMAN; PHENOTYPE; TROPISM; VIRUS ISOLATION; ANIMAL; ANIMAL STRUCTURES; BAGG ALBINO MOUSE; CAMBODIA; DISEASE MODEL; ISOLATION AND PURIFICATION; PATHOGENICITY; PATHOLOGY; RODENT DISEASE; TIME; VIRAL TROPISM; VIROLOGY; VIRULENCE; VIRUS REPLICATION;

ANIMALIA; ARTHROPODA; DENGUE VIRUS; FLAVIVIRUS; MUS;

ANIMAL STRUCTURES; ANIMALS; CAMBODIA; DENGUE; DENGUE VIRUS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; RODENT DISEASES; TIME FACTORS; VIRAL TROPISM; VIRULENCE; VIRUS REPLICATION;

EID: 80051496163     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-398     Document Type: Article

References (46)

1. Phenotypic and genotypic characterization of dengue virus isolates differentiates dengue fever and dengue hemorrhagic fever from dengue shock syndrome. Tuiskunen A, Monteil V, Plumet S, Boubis L, Wahlstrom M, Duong V, Buchy P, Lundkvist A, Tolou H, Leparc-Goffart I, Arch Virol 2011
2. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Rice CM, et al. Science 1985 229 4715 726 33 10.1126/science.4023707 4023707 (Pubitemid 15006393)
3. Flavivirus genome organization, expression, and replication. Chambers TJ, et al. Annu Rev Microbiol 1990 44 649 88 10.1146/annurev.mi.44.100190.003245 2174669
4. Pathogenesis of dengue: challenges to molecular biology. Halstead SB, Science 1988 239 4839 476 81 10.1126/science.3277268 3277268 (Pubitemid 18084309)
5. Dengue: guidelines for diagnosis, treatment, prevention and control - New edition. WHO, World Health Organization 2009
6. Dengue: an escalating problem. Gibbons RV, Vaughn DW, BMJ 2002 324 7353 1563 6 10.1136/bmj.324.7353.1563 12089096 (Pubitemid 34713137)
7. A variant in the CD209 promoter is associated with severity of dengue disease. Sakuntabhai A, et al. Nat Genet 2005 37 5 507 13 10.1038/ng1550 15838506 (Pubitemid 40617279)
8. Development of a novel mouse model for dengue virus infection. An J, et al. Virology 1999 263 1 70 7 10.1006/viro.1999.9887 10544083 (Pubitemid 29493619)
9. Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Blaney JE Jr, et al. Virology 2002 300 1 125 39 10.1006/viro.2002.1528 12202213
10. Study of Dengue virus infection in SCID mice engrafted with human K562 cells. Lin YL, et al. J Virol 1998 72 12 9729 37 9811707
11. Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection. Atrasheuskaya A, et al. FEMS Immunol Med Microbiol 2003 35 1 33 42 10.1111/j.1574-695X.2003.tb00646.x 12589955 (Pubitemid 36173502)
12. New mouse model for dengue virus vaccine testing. Johnson AJ, Roehrig JT, J Virol 1999 73 1 783 6 9847388 (Pubitemid 28565427)
13. Virulence attenuation of Dengue virus due to augmented glycosaminoglycan-binding affinity and restriction in extraneural dissemination. Lee E, et al. J Gen Virol 2006 87 Pt 10 2791 801 16963737 (Pubitemid 44463887)
14. CLEC5A is critical for dengue-virus-induced lethal disease. Chen ST, et al. Nature 2008 453 7195 672 6 10.1038/nature07013 18496526 (Pubitemid 351769308)
15. A mouse-passaged dengue virus strain with reduced affinity for heparan sulfate causes severe disease in mice by establishing increased systemic viral loads. Prestwood TR, et al. J Virol 2008 82 17 8411 21 10.1128/JVI.00611-08 18562532
16. Murine model for dengue virus-induced lethal disease with increased vascular permeability. Shresta S, et al. J Virol 2006 80 20 10208 17 10.1128/JVI.00062-06 17005698 (Pubitemid 44522614)
17. Histopathological and ultrastructural aspects of mice lungs experimentally infected with dengue virus serotype 2. Barreto DF, et al. Mem Inst Oswaldo Cruz 2007 102 2 175 82 10.1590/S0074-02762007005000007 17426882 (Pubitemid 46535879)
18. Liver injury and viremia in mice infected with dengue-2 virus. Paes MV, et al. Virology 2005 338 2 236 46 10.1016/j.virol.2005.04.042 15961136 (Pubitemid 41024860)
19. Manifestation of thrombocytopenia in dengue-2-virus-infected mice. Huang KJ, et al. J Gen Virol 2000 81 Pt 9 2177 82 10950974
20. Both virus and tumor necrosis factor alpha are critical for endothelium damage in a mouse model of dengue virus-induced hemorrhage. Chen HC, et al. J Virol 2007 81 11 5518 26 10.1128/JVI.02575-06 17360740 (Pubitemid 46846992)
21. Amino acid changes in the recombinant Dengue 3 Envelope domain III determine its antigenicity and immunogenicity in mice. Zulueta A, et al. Virus Res 2006 121 1 65 73 10.1016/j.virusres.2006.04.003 16781791 (Pubitemid 44040901)
22. Innate immune responses to dengue virus. Navarro-Sanchez E, Despres P, Cedillo-Barron L, Arch Med Res 2005 36 5 425 35 10.1016/j.arcmed.2005.04.007 16099317 (Pubitemid 41140044)
23. Structure of the dengue virus envelope protein after membrane fusion. Modis Y, et al. Nature 2004 427 6972 313 9 10.1038/nature02165 14737159 (Pubitemid 38133652)
24. Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. Schlesinger JJ, Brandriss MW, Walsh EE, J Gen Virol 1987 68 Pt 3 853 7 3819700 (Pubitemid 17021460)
25. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. Avirutnan P, et al. J Infect Dis 2006 193 8 1078 88 10.1086/500949 16544248
26. Processing of the yellow fever virus nonstructural polyprotein: a catalytically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites. Chambers TJ, Grakoui A, Rice CM, J Virol 1991 65 11 6042 50 1833562
27. N-terminal domains of putative helicases of flavi- and pestiviruses may be serine proteases. Gorbalenya AE, et al. Nucleic Acids Res 1989 17 10 3889 97 10.1093/nar/17.10.3889 2543956 (Pubitemid 19153373)
28. Detection of a trypsin-like serine protease domain in flaviviruses and pestiviruses. Bazan JF, Fletterick RJ, Virology 1989 171 2 637 9 10.1016/0042-6822(89)90639-9 2548336 (Pubitemid 19210412)
29. Models of dengue virus infection. Bente DA, Rico-Hesse R, Drug Discov Today Dis Models 2006 3 1 97 103 10.1016/j.ddmod.2006.03.014 18087566
30. The cellular immune response plays an important role in protecting against dengue virus in the mouse encephalitis model. Gil L, et al. Viral Immunol 2009 22 1 23 30 10.1089/vim.2008.0063 19210225
31. Humanized mice show clinical signs of dengue fever according to infecting virus genotype. Mota J, Rico-Hesse R, J Virol 2009 83 17 8638 45 10.1128/JVI.00581-09 19535452
32. Dengue virus 3 clinical isolates show different patterns of virulence in experimental mice infection. Ferreira GP, et al. Microbes Infect 2010 12 7 546 54 10.1016/j.micinf.2010.03.007 20381635
33. Breakdown of the blood-brain barrier during dengue virus infection of mice. Chaturvedi UC, et al. J Gen Virol 1991 72 Pt 4 859 66 1707947
34. Autoimmune pathogenesis in dengue virus infection. Lin CF, et al. Viral Immunol 2006 19 2 127 32 10.1089/vim.2006.19.127 16817755 (Pubitemid 44050311)
35. Deglycosylation of the NS1 protein of dengue 2 virus, strain 16681: construction and characterization of mutant viruses. Crabtree MB, Kinney RM, Miller BR, Arch Virol 2005 150 4 771 86 10.1007/s00705-004-0430-8 15592895 (Pubitemid 40560824)
36. Cytokine cascade in dengue hemorrhagic fever: implications for pathogenesis. Chaturvedi UC, et al. FEMS Immunol Med Microbiol 2000 28 3 183 8 10.1111/j.1574-695X.2000.tb01474.x 10865168 (Pubitemid 32939398)
37. Shift from a Th1-type response to Th2-type in dengue hemorrhagic fever. Chaturvedi UC, Raghupathy R, Pacsa AS, Elbishbishi EA, Agarwal R, Nagar R, Misra A, Kapoor S, mathur A, Khan MAY, Azizieh F, Curr Sci 1999 76 63 69 (Pubitemid 129558180)
38. Elevated plasma interleukin-10 levels in acute dengue correlate with disease severity. Green S, et al. J Med Virol 1999 59 3 329 34 10.1002/(SICI)1096-9071(199911)59:3<329::AID-JMV12>3.0.CO;2-G 10502265 (Pubitemid 29468075)
39. Characterisation of lymphocyte response and cytokine patterns in patients with dengue fever. Azeredo EL, et al. Immunobiology 2001 204 4 494 507 10.1078/0171-2985-00058 11776403 (Pubitemid 33138110)
40. Circulating levels of tumour necrosis factor-alpha & interferon-gamma in patients with dengue & dengue haemorrhagic fever during an outbreak. Chakravarti A, Kumaria R, Indian J Med Res 2006 123 1 25 30 16567864
41. A model to study cytokine profiles in primary and heterologously secondary Dengue-2 virus infections. Yang KD, et al. Acta Virol 1995 39 1 19 21 7572465
42. Production of cytokines and platelet activating factor in secondary dengue virus infections. Yang KD, Wang CL, Shaio MF, J Infect Dis 1995 172 2 604 5 10.1093/infdis/172.2.604 7622917
43. Dengue haemorrhagic fever. Diagnosis, treatment, prevention and control. WHO, Geneva: WHO 2 1997 12 23
44. Improved molecular detection of dengue virus serotype 1 variants. Reynes JM, et al. J Clin Microbiol 2003 41 8 3864 7 10.1128/JCM.41.8.3864-3867.2003 12904404 (Pubitemid 36994729)
45. Development and validation of real-time one-step reverse transcription-PCR for the detection and typing of dengue viruses. Leparc-Goffart I, et al. J Clin Virol 2009 45 1 61 6 10.1016/j.jcv.2009.02.010 19345140
46. Indirect immunofluorescence for serological diagnosis of dengue virus infections in Swedish patients. Vene S, Mangiafico J, Niklasson B, Clin Diagn Virol 1995 4 1 43 50 10.1016/0928-0197(94)00060-8 15566826